RESUMO
Objective To analyze the relationship between WT1 gene polymorphism rs16754 and prognosis of acute myeloid leukemia (AML) by meta-analysis. Methods Studies published in PubMed, CNKI, WanFang and CBM database were searched by using the search terms 'WT1', 'Polymorphism' and 'Leukemia, Myeloid, Acute', respectively. Deadline was December 1, 2015. Results A total of 11 English articles with a total of 2 789 patients were included. Meta-analysis showed that there was no association between polymorphism rs16754 and complete remission of AML patients (RR=1.02, 95 % CI: 0.99~1.06, P=0.20), overall survival(OS) (HR=0.68, 95 % CI: 0.45~1.02, P=0.06), 5-year OS (RR=1.10, 95 % CI:0.90~1.34, P=0.37) or relapse-free survival (RFS) (HR=0.80, 95 % CI: 0.54~1.19, P=0.27). Conclusion There is no correlation between WT1 gene polymorphism rs16754 and the prognosis of AML.
RESUMO
The genetic variant rs16754 of Wilms tumor gene 1 (WT1) has recently been described as an independent prognostic factor in AML patients. It is of great interest to test whether WT1 single nucleotide polymorphism can be used as a molecular marker in other types of cancer, to improve risk and treatment stratification. We performed sequencing analysis of exons 7 and 9 of WT1, which are known mutational hotspots, in a total of 73 patients with BCR-ABL1-negative myeloproliferative neoplasm (MPN) and 93 healthy controls. No previously reported WT1 mutations were identified in the present study. In Korean patients with BCR-ABL1-negative MPN, WT1 genetic variant rs16754 had no significant impact on clinical outcomes. We observed a significant difference in the allelic frequencies of WT1 rs16754 in Koreans between BCR-ABL1-negative MPN cases and healthy controls. Individuals carrying variant G alleles of WT1 rs16754 showed a relatively low prevalence of BCR-ABL1-negative MPN, compared with those carrying wild A alleles of WT1 rs16754 (Hazard ratio 0.10-0.65, P<0.05). Therefore, possession of the variant G allele of WT1 rs16754 may reduce the risk of developing BCR-ABL1-negative MPN.